.

Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Federal Trade Commission
Merck
Daiichi Sankyo
Citi
Baxter
Moodys
Johnson and Johnson
Queensland Health

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,283,178

« Back to Dashboard

Which drugs does patent 9,283,178 protect, and when does it expire?


Patent 9,283,178 protects OZURDEX and is included in one NDA.

This patent has fifteen patent family members in ten countries.

Summary for Patent: 9,283,178

Title:Methods for treating edema in the eye and intraocular implants for use therefor
Abstract: Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.
Inventor(s): Wong; Vernon G. (Menlo Park, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:14/481,778
Patent Claim Types:
see list of patent claims
Use; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
AllerganOZURDEXdexamethasoneIMPLANT;INTRAVITREAL022315-001Jun 17, 2009RXYesYes► Subscribe► SubscribeTREATMENT OF MACULAR EDEMA► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,283,178

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,071,120Methods for treating neovascularization and intravitreal implants► Subscribe
6,699,493 Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor► Subscribe
8,088,407Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor► Subscribe
8,828,446Method for reducing transplant rejection in the eye and intraocular implants for use therefor► Subscribe
8,043,628Methods for reducing edema► Subscribe
7,767,223Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use► Subscribe
9,592,242Methods for treating edema in the eye and intraocular implants for use therefor► Subscribe
7,846,468Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor► Subscribe
7,625,582Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor► Subscribe
7,033,605Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,283,178

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan2006193532► Subscribe
Japan2004514702► Subscribe
Japan2004210798► Subscribe
Spain2250504► Subscribe
European Patent Office1621219► Subscribe
European Patent Office1550471► Subscribe
European Patent Office1339438► Subscribe
Denmark1339438► Subscribe
Germany60114229► Subscribe
Canada2429998► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Healthtrust
Deloitte
Medtronic
Cerilliant
UBS
Baxter
Citi
Queensland Health
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot